Small interfering RNA (siRNA) molecules hold immense potential for treating diseases by silencing specific genes. Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered efficiently to ...

Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene ...

Silexion Therapeutics' stock surged after the company revealed preclinical findings for SIL-204, its siRNA candidate.

Researchers at the University of Toronto and its hospital partners have developed a method for co-delivering therapeutic RNA ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic ...

Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA ...

Scientists have learned how plants keep viruses from being passed to their offspring, a finding that could ensure healthier ...

This useful study by Gao et al identifies Hspa2 as a heterogeneous transcript in the early embryo and proposes a plausible mechanism showing interactions with Carm1. The authors propose that ...

(NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai ...

A high density of tumor-associated macrophages (TAMs) is associated with poorer prognosis and survival in breast cancer patients. Recent studies have shown that lipid accumulation in TAMs can promote ...